Urging the Director of the Food and Drug Administration to reevaluate the safety of all chemical abortion drugs in light of recent independent studies, and for other purposes.
This is a nonbinding House resolution (H. Res. 803) introduced in the 119th Congress that urges the Director of the Food and Drug Administration (FDA) to reevaluate the safety of all chemical abortion drugs in light of independent studies and to publicly release a comprehensive safety review, including real-world outcomes and complications. The resolution cites prior changes expanding access to chemical abortion (such as removal of certain in-person requirements and mail distribution), notes concerns about potential legal and safety risks, and references the FDA’s recent approval of a new generic version of mifepristone. It frames the issue as one of public health and safety rather than creating new law, and it directs the FDA to provide a transparent safety assessment.
Key Points
- 1The resolution urges the FDA to reevaluate the safety of all chemical abortion drugs, taking into account recent independent studies.
- 2It requires the FDA to publicly release a full safety review of chemical abortion drugs, including real-world outcomes and complications.
- 3It references past federal policy changes that expanded access to chemical abortion (e.g., reduced in-person requirements and mail distribution) and asserts these expansions have raised safety and legal concerns.
- 4It notes that chemical abortions now account for more than half of abortions in the United States, and it mentions concerns about coercion, domestic abuse, and potential misuse.
- 5It highlights the FDA’s September 30, 2025 approval of a new generic version of mifepristone and asserts this could increase the number of abortions and associated harms, while also referencing public funding for providers as an ethical/legal concern.